Boehringer Ingelheim has entered a multi-year agreement with Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, under which, Brigham will conduct a long-term study to assess comparative effectiveness and safety, as well as prescribing patterns, of oral anticoagulants, including Pradaxa, for the reduction of stroke risk in U.S. patients with non-valvular atrial fibrillation (NVAF).   The long-term study aims to better understand the safety and effectiveness of war...